Home›Research›Compare›Gonadorelin vs PT-141
Peptide ComparisonGonadorelin vs PT-141
Both are Reproductive & Hormonal peptides.
Gonadorelin
GnRH
Half-life: ~2-4 minutes
25 providers listed
PT-141
Bremelanotide
Half-life: 2–3 hours
290 providers listed
PT-141 is FDA-approved, while Gonadorelin is not evaluated — the clearest structural difference between them.
Gonadorelin
Evidence
Half-life
~2-4 minutes
PT-141
Evidence
Half-life
2–3 hours
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | Gonadorelin |
| Further along in FDA review | PT-141 |
| Less frequent dosing (longer half-life) | PT-141 |
| Lower typical price per mg | PT-141 |
| More provider options (25 vs 290) | PT-141 |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Gonadorelin
PT-141
Gonadorelin
Effect of post-insemination GnRH analogue administration on pregnancy rates in repeat-breeder cows: compariso…
Increasing gonadorelin hydrochloride dose at the first GnRH of breeding Ovsynch enhances luteinizing hormone…
Therapeutic effects of a pulsatile GnRH pump on adult male patients with congenital hypogonadotropic hypogona…
Efficacy and safety of pulsatile gonadotropin-releasing hormone therapy among patients with idiopathic and fu…
+1 more
PT-141
Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials
Bremelanotide: First Approval
Long-Term Safety and Efficacy of Bremelanotide for Hypoactive Sexual Desire Disorder
Therapeutic Peptides in Aesthetic, Metabolic and Endocrine Conditions: Effects, Safety, Clinical Applications…
+3 more
About Gonadorelin
Synthetic GnRH that binds pituitary GnRH receptors; pulsatile dosing stimulates LH/FSH release; used to maintain HPG axis during TRT
About PT-141
PT-141 is a synthetic analogue of alpha-melanocyte-stimulating hormone (α-MSH) that activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly within the hypothalamus. Unlike peripherally acting agents, it modulates sexual arousal at the CNS level via dopaminergic pathways, independent of vascular mechanisms. Bremelanotide received FDA approval as Vyleesi for hypoactive sexual desire disorder in premenopausal women.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Gonadorelin
No established clinical contraindications
Standard reproductive endocrinology panels establish HPG axis baseline. LH and FSH confirm pituitary response to gonadorelin; testosterone, E2, and SHBG reflect downstream gonadal output.
PT-141
Source: FDA label
FDA prescribing information for bremelanotide identifies transient blood pressure elevation as the primary safety concern. Baseline cardiovascular assessment and BP monitoring are recommended.
PT-141
Oxytocin
Research suggests PT-141 and Oxytocin may produce complementary sexual health effects when combined. PT-141 activates central melanocortin receptors involved in arousal signaling, while oxytocin modulates bonding, reward, and peripheral reproductive pathways.
Antihypertensive medications
Research notes that PT-141 may influence cardiovascular hemodynamics via central melanocortin pathways. Combined use with antihypertensive medications may require monitoring. Consult your prescriber before combining.
Gonadorelin
PT-141
Where to source these peptides
Gonadorelin
25 listed
Browse directory →
Providers offeringPT-141
290 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Reproductive & Hormonal Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated July 20, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Gonadorelin vs PT-141 — Per-mg Price Comparison. Retrieved July 22, 2026, from https://peptidebase.io/peptides/compare/gonadorelin/pt-141